Cargando…

Oral anticoagulant switching in patients with atrial fibrillation: a scoping review

INTRODUCTION: Oral anticoagulants (OACs) prevent stroke in patients with atrial fibrillation (AF). Several factors may cause OAC switching. OBJECTIVES: To examine the phenomenon of OAC switching in patients with AF, including all available evidence; frequency and patterns of switch, clinical outcome...

Descripción completa

Detalles Bibliográficos
Autores principales: Adelakun, Adenike R, Turgeon, Ricky D, De Vera, Mary A, McGrail, Kimberlyn, Loewen, Peter S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10151984/
https://www.ncbi.nlm.nih.gov/pubmed/37185198
http://dx.doi.org/10.1136/bmjopen-2023-071907
_version_ 1785035657768337408
author Adelakun, Adenike R
Turgeon, Ricky D
De Vera, Mary A
McGrail, Kimberlyn
Loewen, Peter S
author_facet Adelakun, Adenike R
Turgeon, Ricky D
De Vera, Mary A
McGrail, Kimberlyn
Loewen, Peter S
author_sort Adelakun, Adenike R
collection PubMed
description INTRODUCTION: Oral anticoagulants (OACs) prevent stroke in patients with atrial fibrillation (AF). Several factors may cause OAC switching. OBJECTIVES: To examine the phenomenon of OAC switching in patients with AF, including all available evidence; frequency and patterns of switch, clinical outcomes, adherence, patient-reported outcomes, reasons for switch, factors associated with switch and evidence gaps. DESIGN: Scoping review. DATA SOURCES: MEDLINE, Embase and Web of Science, up to January 2022. RESULTS: Of the 116 included studies, 2/3 examined vitamin K antagonist (VKA) to direct-acting OAC (DOAC) switching. Overall, OAC switching was common and the definition of an OAC switch varied across. Switching from VKA to dabigatran was the most prevalent switch type, but VKA to apixaban has increased in recent years. Patients on DOAC switched more to warfarin than to other DOACs. OAC doses involved in the switches were hardly reported and patients were often censored after the first switch. Switching back to a previously taken OAC (frequently warfarin) occurred in 5%–21% of switchers. The risk of ischaemic stroke and gastrointestinal bleeding in VKA to DOAC switchers compared with non-switchers was conflicting, while there was no difference in the risk of other types of bleeding. The risk of ischaemic stroke in switchers from DOAC versus non-switchers was conflicting. Studies evaluating adherence found no significant changes in adherence after switching from VKA to DOAC, however, an increase in satisfaction with therapy were reported. Reasons for OAC switch, and factors associated with OAC switch were mostly risk factors for stroke and bleeding. Clinical outcomes, adherence and patient-reported outcomes were sparse for switches from DOACs. CONCLUSIONS: OAC switching is common in patients with AF and patients often switch back to an OAC they have previously been on. There are aspects of OAC switching that have received little study, especially in switches from DOACs.
format Online
Article
Text
id pubmed-10151984
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-101519842023-05-03 Oral anticoagulant switching in patients with atrial fibrillation: a scoping review Adelakun, Adenike R Turgeon, Ricky D De Vera, Mary A McGrail, Kimberlyn Loewen, Peter S BMJ Open Cardiovascular Medicine INTRODUCTION: Oral anticoagulants (OACs) prevent stroke in patients with atrial fibrillation (AF). Several factors may cause OAC switching. OBJECTIVES: To examine the phenomenon of OAC switching in patients with AF, including all available evidence; frequency and patterns of switch, clinical outcomes, adherence, patient-reported outcomes, reasons for switch, factors associated with switch and evidence gaps. DESIGN: Scoping review. DATA SOURCES: MEDLINE, Embase and Web of Science, up to January 2022. RESULTS: Of the 116 included studies, 2/3 examined vitamin K antagonist (VKA) to direct-acting OAC (DOAC) switching. Overall, OAC switching was common and the definition of an OAC switch varied across. Switching from VKA to dabigatran was the most prevalent switch type, but VKA to apixaban has increased in recent years. Patients on DOAC switched more to warfarin than to other DOACs. OAC doses involved in the switches were hardly reported and patients were often censored after the first switch. Switching back to a previously taken OAC (frequently warfarin) occurred in 5%–21% of switchers. The risk of ischaemic stroke and gastrointestinal bleeding in VKA to DOAC switchers compared with non-switchers was conflicting, while there was no difference in the risk of other types of bleeding. The risk of ischaemic stroke in switchers from DOAC versus non-switchers was conflicting. Studies evaluating adherence found no significant changes in adherence after switching from VKA to DOAC, however, an increase in satisfaction with therapy were reported. Reasons for OAC switch, and factors associated with OAC switch were mostly risk factors for stroke and bleeding. Clinical outcomes, adherence and patient-reported outcomes were sparse for switches from DOACs. CONCLUSIONS: OAC switching is common in patients with AF and patients often switch back to an OAC they have previously been on. There are aspects of OAC switching that have received little study, especially in switches from DOACs. BMJ Publishing Group 2023-04-25 /pmc/articles/PMC10151984/ /pubmed/37185198 http://dx.doi.org/10.1136/bmjopen-2023-071907 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Cardiovascular Medicine
Adelakun, Adenike R
Turgeon, Ricky D
De Vera, Mary A
McGrail, Kimberlyn
Loewen, Peter S
Oral anticoagulant switching in patients with atrial fibrillation: a scoping review
title Oral anticoagulant switching in patients with atrial fibrillation: a scoping review
title_full Oral anticoagulant switching in patients with atrial fibrillation: a scoping review
title_fullStr Oral anticoagulant switching in patients with atrial fibrillation: a scoping review
title_full_unstemmed Oral anticoagulant switching in patients with atrial fibrillation: a scoping review
title_short Oral anticoagulant switching in patients with atrial fibrillation: a scoping review
title_sort oral anticoagulant switching in patients with atrial fibrillation: a scoping review
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10151984/
https://www.ncbi.nlm.nih.gov/pubmed/37185198
http://dx.doi.org/10.1136/bmjopen-2023-071907
work_keys_str_mv AT adelakunadeniker oralanticoagulantswitchinginpatientswithatrialfibrillationascopingreview
AT turgeonrickyd oralanticoagulantswitchinginpatientswithatrialfibrillationascopingreview
AT deveramarya oralanticoagulantswitchinginpatientswithatrialfibrillationascopingreview
AT mcgrailkimberlyn oralanticoagulantswitchinginpatientswithatrialfibrillationascopingreview
AT loewenpeters oralanticoagulantswitchinginpatientswithatrialfibrillationascopingreview